Scott Rocklage Continues to Expand Reserach for DM1 Disorders

Recently Expansion Therapeutics raised over $55.3 million for research for the development of drugs that target genetic diseases that cause adult muscular dystrophy. The financing was lead by several companies including 5AM Ventures.

DM1 a substance that causes these genetic repeat disorders is caused by production of toxic molecules that turn into proteins inside the cells. This leads to problems with the heart, nervous system, respiratory system, muscles, stomach, and hormones. This can affect entire families and to date there is no known treatment for the disease. Read more: Scott Rocklage | Ideamesch and Scott Rocklage | Angel

Expansion Therapeutics specializes in developing drugs that target diseases caused by RNA. It focuses on disease that have no treatment or cure. Scott M. Rocklage managing partner of 5M Ventures and chairman of the board of directors of Expansion Therapeutics says the drugs they develop are based on research performed by Matthew D. Disney Ph.D of Scripps Research Institute.

Rocklage said that Disney was the key scientific founder of the team The company has put together a research team and a plan to advance the field of RNA medicine. They want to develop new medicines for patients that have few treatment options available.

Scott Rocklage went to the University of California Berkley. He received a B.A. in Chemistry. Later he went on to receive a Ph.D in Chemistry from the Massachusetts Institute of Technology. While at MIT he conducted research and worked in the lab.

In 2005, he received the Nobel Peace Prize in Chemistry. He joined 5AM Ventures in 2003 as a venture partner and later became a managing partner. Dr. Rocklage was responsible for FDA approval of three drugs. He has submitted numerous drugs for clinical trail studies.

Scott Rocklage owns over 30 US patents and many of his articles published have been peer reviewed. At one time he was chairman and CEO of Cubist Pharmaceuticals and held many R & D positions at different companies.

Leave a Reply

Your email address will not be published. Required fields are marked *